Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mandelic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 2/20 | 0.56 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.46 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.95 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.95 |
| ▸ | CES2 | O00748 | 2/20 | 0.60 |
| ▸ | CES1 | P23141 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mandelic Acid SCHEMBL9617552 | 1.00 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1374278 | 1.00 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL1050 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL29777368 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL21647917 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL5313046 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL165161 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL255601 | 0.97 | LMNA (1.00) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL28129991 | 0.95 | LMNA (0.86) | LMNAMAPK1CES2CES1SRC | |
| Mandelic Acid SCHEMBL9185770 | 0.95 | LMNA (0.95) | LMNAMAPK1CES2CES1SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112694488-B | Synthesis method of L-type cefamandole nafate | 苏州盛达药业有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-113354534-A | Preparation method of D- (-) -formyl mandelic acid chloride | 江西科苑生物股份有限公司 | 2021-09-07 | — | — | CN | claimed |
| CN-112694488-A | Synthesis method of L-type cefamandole nafate | 苏州盛达药业有限公司 | 2021-04-23 | — | — | CN | claimed |
| CN-110204557-A | A kind of preparation method of Mandokef sodio-derivative | 苏州盛达药业有限公司 | 2019-09-06 | — | — | CN | claimed |
| CN-106565750-B | A kind of synthetic method of dextrorotation Mandokef acid | 哈药集团制药总厂 | 2018-09-11 | — | — | CN | claimed |
| CN-106565750-A | Synthesis method for dextrorotation cefamandole nafate | 哈药集团制药总厂 | 2017-04-19 | — | — | CN | claimed |
| CN-106380526-A | O-alpha-methyl mandelate-N-trimethyl chitosan quaternary ammonium salt as well as preparation method and application thereof | 湖南工业大学 | 2017-02-08 | — | — | CN | claimed |
| CN-105399754-A | Preparation method for sodium cefamandole | CHINA UNION CHEMPHARMA (SUZHOU) CO LTD | 2016-03-16 | — | — | CN | claimed |
| CN-103319335-B | Preparation method of D-(-)-O-methyl mandelic acid chloride | ZHANG ZHENXIA | 2014-12-03 | — | — | CN | claimed |
| CN-103319335-A | Preparation method of D-(-)-O-methyl mandelic acid chloride | ZHANG ZHENXIA | 2013-09-25 | — | — | CN | claimed |
| CN-102816172-A | Preparation process of cefamandole nafate | CHINA UNION CHEMPHARMA SUZHOU CO LTD | 2012-12-12 | — | — | CN | claimed |
| CN-101880290-A | Preparation method of cefamandole nafate | HAINAN NEW ZHONGZHENG PHARMACEUTICAL CO LTD | 2010-11-10 | — | — | CN | claimed |
| CN-101085781-B | Method for preparing cefonicid or its medicinal salt and intermediate | SHENZHEN SALUBRIS PHARM CO LTD | 2010-05-26 | — | — | CN | claimed |
| CN-101085781-A | Method for preparing cefonicid or its medicinal salt and intermediate | SHENZHEN SALUBRIS PHARMACEUTIC (CN) | 2007-12-12 | — | — | CN | claimed |
| CN-117430557-A | Preparation and application of eutectic crystal form of dibazoles and mandelic acid and pharmaceutical composition | 上海应用技术大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-112552343-B | Axial chiral naphthalene-indole phosphine catalyst and preparation method and application thereof | 江苏师范大学 | 2023-03-14 | — | — | CN | disclosed |
| CN-112694488-B | Synthesis method of L-type cefamandole nafate | 苏州盛达药业有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-0253785-B1 | EFFICIENT STEREOCONSERVATIVE SYNTHESES OF 1-SUBSTITUTED (S)- AND (R)-2-AMINOMETHYLPYRROLIDINES AND INTERMEDIATES THEREIN | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1992-11-11 | — | — | EP | disclosed |
| EP-0253785-A1 | Efficient stereoconservative syntheses of 1-substituted (S)- and (R)-2-aminomethylpyrrolidines and intermediates therein | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1988-01-20 | — | — | EP | disclosed |
| EP-0064964-B1 | THERAPEUTICALLY USEFUL 1-ALKYL-2-AMINOTETRALIN DERIVATIVES | Astra Läkemedel Aktiebolag (SE) | 1984-08-08 | — | — | EP | disclosed |